SEARCH

SEARCH BY CITATION

References

  • 1
    Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med 2010; 38(4 Suppl.): S5029.
  • 2
    Beckman MG, Hooper C, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38(4 Suppl.): S495501.
  • 3
    Centers for Disease Control and Prevention. Venous thromboembolism in adult hospitalizations - United States, 2007–2009. Morb Mortal Wkly Rep 2012; 61: 4014.
  • 4
    Silverstein MD, Heit J, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 58593.
  • 5
    Beckman MG, Craig Hooper W, Critchley SE, Ortel TL. Venous thromboembolism. A public health concern. Am J Prev Med 2010; 38(6 Suppl. 4): S495501.
  • 6
    Cushman M. Inherited risk factors for venous thrombosis. Hematology 2005; 1: 4527.
  • 7
    Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005; 112.
  • 8
    Salzman EW, Neri LL. Adhesiveness of blood platelets in uremia. Thromb Diath Haemorrh 1966; 15: 8492.
  • 9
    Lewis JH, Zucker MB, Fergunson JH. Bleeding tendency in uremia. Blood 1956; 11: 10736.
  • 10
    Horowitz HI, Stein IM, Cohen BD, White JG. Further studies on the platelet Inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding. Am J Med 1970; 49: 33645.
  • 11
    Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day SS, Smith WL, Pinca E, Patrignani P, Patrono C. Reduced platelet thromboxane formation in uremia: evidence for a functional cyclooxygenase defect. J Clin Invest 1983; 71: 7628.
  • 12
    Mathias FR, Palinski W. Prostaglandin-endoperoxides and cyclic 3′5′-AMP in platelets of patients with uremia. Thromb Haemost 1977; 38: 34.
  • 13
    Sloand EM, Sloand JA, Prodouz K, Klein HG, Yu MW, Harvath L, Fricke W. Reduction of platelet glycoprotein Ib in uremia. Br J Haematol 1991; 77: 37581.
  • 14
    Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254: 1329.
  • 15
    Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 60914.
  • 16
    Ifudu O, Delaney VB, Barth RH, Friedman EA. Deep vein thrombosis in end-stage renal disease. ASAIO J 1994; 40: 1035.
  • 17
    Tveit DP, Hypolite IO, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC. Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 2002; 39: 10117.
  • 18
    Ocak G, van Stralen KJ, Rosendaal FR, Verduijn M, Ravani P, Palsson R, Leivestad T, Hoitsma AJ, Ferrer-Alamar M, Finne P, De Meester J, Wanner C, Dekker FW, Jager KJ. Mortality due pulmonary embolism, myocardial infarstion and stroke among incident hemodialysis patients. J Thromb Haemost 2012; 10: 248493.
  • 19
    Winkelmayer W, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011; 6: 26628.
  • 20
    Demer LL, Tintut Y, Parhami F. Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens 2002; 11: 43743.
  • 21
    Fusaro M, Crepaldi G, Maggi S, D’Angelo A, Calo L, Miozzo D, Fornasieri A, Gallieni M. Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies. Curr Vasc Pharmacol 2011; 9: 7639.
  • 22
    Gallieni M, Cozzolino M, Ronga C, Brancaccio D. Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008; 4: 4889.
  • 23
    Borawski J, Zbroch E, Rydzewska-Rosolowska A, Pawlak K, Mysliwiec M. Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II. J Nephrol 2007; 20: 3702.
  • 24
    Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012; 46: e10.
  • 25
    Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009; 54: 3342.
  • 26
    Monreal M, Falga C, Valle R, Barba R, Bosco J, Beato JL, Maestre A. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119: 10739.